Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Resistance to Ibrutinib in B Cell Malignancies: One Size Does Not Fit All.

Shah B, Zhao X, Silva AS, Shain KH, Tao J.

Trends Cancer. 2018 Mar;4(3):197-206. doi: 10.1016/j.trecan.2018.01.004. Epub 2018 Feb 21. Review.

PMID:
29506670
2.
3.

Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.

Fradley MG, Groarke JD, Laubach J, Alsina M, Lenihan DJ, Cornell RF, Maglio M, Shain KH, Richardson PG, Moslehi J.

Br J Haematol. 2018 Jan;180(2):271-275. doi: 10.1111/bjh.14970. Epub 2017 Oct 19.

PMID:
29048105
4.

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.

Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, Zhang L, Fu K, Bi C, Li J, Jiang H, Meads MB, Jacobson T, Silva M, Distler A, Darville L, Zhang L, Han Y, Rebatchouk D, Di Liberto M, Moscinski LC, Koomen JM, Dalton WS, Shain KH, Wang M, Sotomayor E, Tao J.

Nat Commun. 2017 Apr 18;8:14920. doi: 10.1038/ncomms14920.

5.

An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma.

Silva A, Silva MC, Sudalagunta P, Distler A, Jacobson T, Collins A, Nguyen T, Song J, Chen DT, Chen L, Cubitt C, Baz R, Perez L, Rebatchouk D, Dalton W, Greene J, Gatenby R, Gillies R, Sontag E, Meads MB, Shain KH.

Cancer Res. 2017 Jun 15;77(12):3336-3351. doi: 10.1158/0008-5472.CAN-17-0502. Epub 2017 Apr 11.

PMID:
28400475
6.

Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.

Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E.

Lancet Oncol. 2017 Jan;18(1):112-121. doi: 10.1016/S1470-2045(16)30627-1. Epub 2016 Dec 4.

PMID:
27927582
7.

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.

Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer AA, Grant S, Dai Y, Shain KH, Meads M, Landesman Y, Sullivan DM.

Oncotarget. 2016 Nov 29;7(48):78896-78909. doi: 10.18632/oncotarget.12969.

8.

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.

Turner JG, Dawson JL, Grant S, Shain KH, Dalton WS, Dai Y, Meads M, Baz R, Kauffman M, Shacham S, Sullivan DM.

J Hematol Oncol. 2016 Aug 24;9(1):73. doi: 10.1186/s13045-016-0304-z.

9.

Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide.

Rollison DE, Komrokji R, Lee JH, Hampras S, Fulp W, Fisher K, Baz R, Nishihori T, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Sullivan D, Alsina M, Dalton W, Shain KH.

Leuk Lymphoma. 2017 Mar;58(3):560-568. doi: 10.1080/10428194.2016.1207763. Epub 2016 Jul 18.

PMID:
27424609
10.

Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.

Rollison DE, Shain KH, Lee JH, Hampras SS, Fulp W, Fisher K, Al Ali NH, Padron E, Lancet J, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Dalton W, List A, Komrokji RS.

Cancer Med. 2016 Jul;5(7):1694-701. doi: 10.1002/cam4.721. Epub 2016 Apr 20.

11.

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.

Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S.

Blood. 2016 May 26;127(21):2561-8. doi: 10.1182/blood-2015-11-682518. Epub 2016 Mar 1.

12.

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment.

Nishihori T, Song J, Shain KH.

Curr Hematol Malig Rep. 2016 Apr;11(2):118-26. doi: 10.1007/s11899-016-0308-3. Review.

13.

Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma.

Meads MB, Fang B, Mathews L, Gemmer J, Nong L, Rosado-Lopez I, Nguyen T, Ring JE, Matsui W, MacLeod AR, Pachter JA, Hazlehurst LA, Koomen JM, Shain KH.

Oncogene. 2016 May;35(21):2723-34. doi: 10.1038/onc.2015.334. Epub 2015 Sep 21.

14.

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells.

Silva A, Jacobson T, Meads M, Distler A, Shain K.

J Vis Exp. 2015 Jul 15;(101):e53070. doi: 10.3791/53070.

15.

A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.

Griffin PT, Ho VQ, Fulp W, Nishihori T, Shain KH, Alsina M, Baz RC.

Cancer. 2015 Oct 15;121(20):3622-30. doi: 10.1002/cncr.29533. Epub 2015 Jul 6.

16.

Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides.

Fang B, Hoffman MA, Mirza AS, Mishall KM, Li J, Peterman SM, Smalley KS, Shain KH, Weinberger PM, Wu J, Rix U, Haura EB, Koomen JM.

Methods. 2015 Jun 15;81:41-9. doi: 10.1016/j.ymeth.2015.03.006. Epub 2015 Mar 14.

17.

The tumor microenvironment shapes hallmarks of mature B-cell malignancies.

Shain KH, Dalton WS, Tao J.

Oncogene. 2015 Sep 3;34(36):4673-82. doi: 10.1038/onc.2014.403. Epub 2015 Feb 2. Review.

18.

An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.

Nishihori T, Baz R, Shain K, Kim J, Ochoa-Bayona JL, Yue B, Sullivan D, Dalton W, Alsina M.

Eur J Haematol. 2015 Nov;95(5):426-35. doi: 10.1111/ejh.12509. Epub 2015 Mar 12.

19.

Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome.

Nishihori T, Komrokji R, Shain K, Anasetti C.

Bone Marrow Transplant. 2015 Feb;50(2):296-7. doi: 10.1038/bmt.2014.233. Epub 2014 Oct 20. No abstract available.

PMID:
25330222
20.

A preclinical assay for chemosensitivity in multiple myeloma.

Khin ZP, Ribeiro ML, Jacobson T, Hazlehurst L, Perez L, Baz R, Shain K, Silva AS.

Cancer Res. 2014 Jan 1;74(1):56-67. doi: 10.1158/0008-5472.CAN-13-2397. Epub 2013 Dec 5.

21.

The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies.

Shain KH, Tao J.

Oncogene. 2014 Aug 7;33(32):4107-13. doi: 10.1038/onc.2013.379. Epub 2013 Sep 16. Review.

22.

Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma.

Baz RC, Shain KH, Hussein MA, Lee JH, Sullivan DM, Oliver EF, Nardelli LA, Nodzon LA, Zhao X, Ochoa-Bayona JL, Nishihori T, Dalton WS, Alsina M.

Am J Hematol. 2014 Jan;89(1):62-7. doi: 10.1002/ajh.23587.

23.

High-dose melphalan produces favorable response in a patient with multiple myeloma and coexisting essential thrombocythemia with JAK2 mutation.

Nishihori T, Hassoun Y, Zhang L, Shain K, Alsina M, Kharfan-Dabaja MA.

Bone Marrow Transplant. 2014 Jan;49(1):148-9. doi: 10.1038/bmt.2013.117. Epub 2013 Aug 12. No abstract available.

PMID:
23933759
24.

Sequence of novel agents in multiple myeloma: an instrumental variable analysis.

Baz R, Miladinovic B, Patel A, Ho VQ, Shain KH, Alsina M, Nishihori T, Ochoa-Bayona JL, Sullivan DM, Dalton WS, Djulbegovic B.

Leuk Res. 2013 Sep;37(9):1077-82. doi: 10.1016/j.leukres.2013.06.005. Epub 2013 Jun 25.

PMID:
23809054
25.

Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma.

Nishihori T, Ochoa-Bayona JL, Kim J, Pidala J, Shain K, Baz R, Sullivan D, Jim HS, Anasetti C, Alsina M.

Bone Marrow Transplant. 2013 Sep;48(9):1179-84. doi: 10.1038/bmt.2013.37. Epub 2013 Apr 1.

26.

Stemness of B-cell progenitors in multiple myeloma bone marrow.

Boucher K, Parquet N, Widen R, Shain K, Baz R, Alsina M, Koomen J, Anasetti C, Dalton W, Perez LE.

Clin Cancer Res. 2012 Nov 15;18(22):6155-68. doi: 10.1158/1078-0432.CCR-12-0531. Epub 2012 Sep 17.

27.

Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation.

Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, Maciejewski JP, List AF, Epling-Burnette PK, Araten DJ.

Blood Cancer J. 2012 Mar;2(3):e63. doi: 10.1038/bcj.2012.7. Epub 2012 Mar 23. No abstract available.

28.

Metastatic myeloma?

Shain K.

Blood. 2012 Jun 14;119(24):5612-3. doi: 10.1182/blood-2012-04-417337. No abstract available.

29.

Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.

Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M.

Br J Haematol. 2012 Jun;157(5):553-63. doi: 10.1111/j.1365-2141.2012.09099.x. Epub 2012 Mar 26.

30.

Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.

Xiang Y, Remily-Wood ER, Oliveira V, Yarde D, He L, Cheng JQ, Mathews L, Boucher K, Cubitt C, Perez L, Gauthier TJ, Eschrich SA, Shain KH, Dalton WS, Hazlehurst L, Koomen JM.

Mol Cell Proteomics. 2011 Nov;10(11):M110.005520. doi: 10.1074/mcp.M110.005520. Epub 2011 Aug 16.

31.

Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience.

Lebovic D, Zhang L, Alsina M, Nishihori T, Shain KH, Sullivan D, Ochoa-Bayona JL, Kharfan-Dabaja MA, Baz R.

Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):507-11. doi: 10.1016/j.clml.2011.06.010. Epub 2011 Aug 2.

PMID:
21813352
32.

Deletions of Xp22.2 including PIG-A locus lead to paroxysmal nocturnal hemoglobinuria.

O'Keefe CL, Sugimori C, Afable M, Clemente M, Shain K, Araten DJ, List A, Epling-Burnette PK, Maciejewski JP.

Leukemia. 2011 Feb;25(2):379-82. doi: 10.1038/leu.2010.274. Epub 2010 Nov 30. No abstract available.

PMID:
21116280
33.

Environmental-mediated drug resistance: a target for multiple myeloma therapy.

Shain KH, Dalton WS.

Expert Rev Hematol. 2009 Dec;2(6):649-62. doi: 10.1586/ehm.09.55. Review.

PMID:
21082957
34.

Analysis of the ability of catcher's masks to attenuate head accelerations on impact with a baseball.

Shain KS, Madigan ML, Rowson S, Bisplinghoff J, Duma SM.

Clin J Sport Med. 2010 Nov;20(6):422-7. doi: 10.1097/JSM.0b013e3181f7db25.

PMID:
21079437
35.

Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.

Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, Shain KH, Hazlehurst LA, Alsina M, Chen DT, Beg AA, Dalton WS.

Cancer Res. 2009 Dec 15;69(24):9367-75. doi: 10.1158/0008-5472.CAN-09-2616.

36.

Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation.

Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA, Dalton WS.

Cancer Res. 2009 Feb 1;69(3):1009-15. doi: 10.1158/0008-5472.CAN-08-2419. Epub 2009 Jan 20.

37.

Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP.

Perez LE, Parquet N, Shain K, Nimmanapalli R, Alsina M, Anasetti C, Dalton W.

J Immunol. 2008 Feb 1;180(3):1545-55.

38.

Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects.

Burdelya L, Kujawski M, Niu G, Zhong B, Wang T, Zhang S, Kortylewski M, Shain K, Kay H, Djeu J, Dalton W, Pardoll D, Wei S, Yu H.

J Immunol. 2005 Apr 1;174(7):3925-31.

39.

Targeting the bone marrow microenvironment in hematologic malignancies.

Dalton WS, Hazlehurst L, Shain K, Landowski T, Alsina M.

Semin Hematol. 2004 Apr;41(2 Suppl 4):1-5. Review.

PMID:
15190509
40.

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells.

Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H.

Nat Med. 2004 Jan;10(1):48-54. Epub 2003 Dec 21. Erratum in: Nat Med. 2004 Feb;10(2):209.

41.

Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.

Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, Saporta S, Boulware D, Moscinski L, Alsina M, Dalton WS.

Cancer Res. 2003 Nov 15;63(22):7900-6.

42.

Regulation of caspase expression and apoptosis by adenomatous polyposis coli.

Chen T, Yang I, Irby R, Shain KH, Wang HG, Quackenbush J, Coppola D, Cheng JQ, Yeatman TJ.

Cancer Res. 2003 Aug 1;63(15):4368-74.

43.
45.

Multiple Myeloma: New Insights and Therapeutic Approaches.

Anderson KC, Kyle RA, Dalton WS, Landowski T, Shain K, Jove R, Hazlehurst L, Berenson J.

Hematology Am Soc Hematol Educ Program. 2000:147-165.

PMID:
11701540
47.

The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance.

Shain KH, Landowski TH, Dalton WS.

Curr Opin Oncol. 2000 Nov;12(6):557-63. Review.

PMID:
11085455
48.
49.
50.

Constitutive RelB activation in v-Src-transformed fibroblasts: requirement for IkappaB degradation.

Shain KH, Jove R, Olashaw NE.

J Cell Biochem. 1999 May 1;73(2):237-47.

PMID:
10227387

Supplemental Content

Support Center